Australija - engleski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - methoxy polyethylene glycol-epoetin beta, quantity: 0.25 mg - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium sulfate; methionine; mannitol; poloxamer; water for injections - mircera is indicated for the treatment of anaemia associated with chronic kidney disease (ckd).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - methoxy polyethylene glycol-epoetin beta, quantity: 0.15 mg - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; methionine; poloxamer; sodium sulfate; mannitol; water for injections - mircera is indicated for the treatment of anaemia associated with chronic kidney disease (ckd).

Izrael - engleski - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 10 mcg / 0.4 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Izrael - engleski - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 100 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Izrael - engleski - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 150 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age.aranesp ® is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Izrael - engleski - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 20 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Izrael - engleski - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 30 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Izrael - engleski - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 40 mcg / 0.4 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Izrael - engleski - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 50 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Izrael - engleski - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 60 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age